Not Signed In -
Diabetic Kidney Problems |
|
|
Clinical Trial: Safety and Efficacy of FTY720 in Adult Patients who Receive a Kidney Transplant
This study is currently recruiting patients.
|
Purpose
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Kidney Transplantation | Drug: FTY720 | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Study start: December 2004
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Patients undergoing their first kidney transplant
- Male or female age 18 to 65 years
Exclusion Criteria:
- Patients in need of second kidney transplant or multi-organ transplants.
Location and Contact Information
Alabama
The University of Alabama (Birmingham), Birmingham, Alabama, 35294, United States; Recruiting
Patsy Jones, RN 205-934-1389 patsyj@uab.edu
Carlton Young, MD, Principal Investigator
Carlton Young, MD, Principal Investigator
Missouri
Washington University (St. Louis)/Barnes Jewish Hospital, St. Louis, Missouri, 63110, United States; Recruiting
Mark Lockwood 314-362-4109 lockwoodm@msnotes.wustl.edu
Kim Knolhoff 314-362-8351 knolhoffk@msnotes.wustl.edu
Daniel C Brennan, MD, Principal Investigator
Kim Knolhoff 314-362-8351 knolhoffk@msnotes.wustl.edu
Daniel C Brennan, MD, Principal Investigator
Ohio
Ohio State University College of Medicine (OSU), Columbus, Ohio, 43210, United States; Recruiting
Jill Baxa 614-293-5414 baxa-1@medctr.osu.edu
Tomasina Wall 614-293-8195 wall-2@medctr.osu.edu
Ronald M Ferguson, MD, Principal Investigator
Tomasina Wall 614-293-8195 wall-2@medctr.osu.edu
Ronald M Ferguson, MD, Principal Investigator
Oregon
Oregon Health Sciences University School of Medicine (OHSU)/Oregon Health Sciences University Hospital, Portland, Oregon, 97239, United States; Not yet recruiting
Ted Norton 503-494-8976 nortont@ohsu.edu
Tammy LaBeck 503-494-6893 labeckt@ohsu.edu
Muralikrishna Golconda, MD, Principal Investigator
Tammy LaBeck 503-494-6893 labeckt@ohsu.edu
Muralikrishna Golconda, MD, Principal Investigator
More Information
Study ID Numbers: CFTY720A2307
Record last reviewed: December 2004
Last Updated: December 20, 2004
Record first received: December 20, 2004
ClinicalTrials.gov Identifier: NCT00099801
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: December 2004
Last Updated: December 20, 2004
Record first received: December 20, 2004
ClinicalTrials.gov Identifier: NCT00099801
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- American Diabetes Association
- ClinicalTrials.gov: Diabetic Nephropathies (National Institutes of Health)
email this page
print this page
bookmark this page
feedback on this page
